3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
57
Pancreatic Neoplasms
39
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
20
Neoplasms
17
Neoplasm Metastasis
11
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Ovarian Neoplasms
8
Melanoma
7
Head and Neck Neoplasms
6
Breast Neoplasms, Male
6
Adenocarcinoma
6
Urinary Bladder Neoplasms
5
Inflammatory Breast Neoplasms
5
Carcinoma
5
Sarcoma
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Pancreatic Diseases
4
Fallopian Tube Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Ovarian Epithelial
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Pancreatic Adenocarcinoma
3
Esophageal Neoplasms
3
Endocrine System Diseases
3
Endocrine Gland Neoplasms
3
Digestive System Neoplasms
3
Digestive System Diseases
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA